How legislation on decisional capacity can negatively affect the feasibility of clinical trials in patients with dementia

Drugs and Aging

Volumn 29, Issue 8, 2012, Pages 607-614

  Galeotti, Francesca ^a   Vanacore, Nicola ^a   Gainotti, Sabina ^a   Izzicupo, Fabio ^b   Menniti Ippolito, Francesca ^a   Petrini, Carlo ^a   Chiarotti, Flavia ^a   Chattat, Rabih ^c   Raschetti, Roberto ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UO Hospice Area Vasta 1 ^*  (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ALZHEIMER DISEASE; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LAW; MEDICAL ETHICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REVIEW;

EID: 84864142617     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11630810-000000000-00000     Document Type: Review

References (41)

1. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population- based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54 (11 Suppl. 5): S4-9
2. Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat Rev Drug Discov 2006; 5: 64-74
3. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly: I. A conceptual review. J Am Geriatr Soc 1986; 34: 711-21
4. Lanctôt KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59 (10): 550-61
5. Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; (2): CD002852
6. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: metaanalysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191-210
7. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimers disease. N Engl J Med 2006; 355 (15): 1525-38
8. Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring (MD): US FDA [online]. Available from URL: http://www.fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/DrugSafetyInformationforHeath careProfessionals/ PublicHealthAdvisories/ucm053171.htm [Accessed 2012 Apr]
9. Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Ottawa (ON): Health Canada, 2005 Jun 15 [online]. Available from URL: http://www.hc-sc.gc.ca/ahc-asc/ media/advisories-avis/-2005/2005-63-eng.php [Accessed 2012 Apr]
10. European Agency for the Evaluation of Medicinal Products (EMEA). Cerebrovascular events and increased mortality in eldery patients with dementia. London: EMEA, 2004
11. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010; 170: 96-103
12. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008; 179:438-46
13. Trifirò G, Sini G, Sturkenboom MC, et al. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. Int Clin Psychopharmacol 2010; 25: 22-8
14. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54: 1965-71
15. Viale D, Mereu RM, Asuni G, et al. Behave-AD-FW Behavioral Pathology in Alzheimers Disease Rating Scale: reliability of the Italian version of the scale. G Gerontol 2005; 53: 20-32
16. Izzicupo F, Vanacore N, Galeotti F, et al. Parametri per la valutazione della capacità di esprimere consenso al trattamento e strumenti per la loro misurazione. In: Petrini C, editor. Il Consenso informato al trattamento dei soggetti affetti da demenza; aspetti etici, deontologici e giuridici. Rapporto ISTISAN 2008; 33: 14-22
17. Gainotti S, Fusari Imperatori S, Spila-Alegiani S, et al. How are the interests of incapacitated research participants protected through legislation? An Italian study on legal agency for dementia patients. PLoS One 2010; 5: e11150
18. Gurrera RJ, Moye J, Karel MJ, et al. Cognitive performance predicts treatment decisional abilities in mild to moderate dementia. Neurology 2006; 66: 1367-72
19. Department of Veterans Affairs. Clinical assessment for competency determination: a practice guideline for psychologist. Milwaukee (WI): Department of Veterans affairs, National Centers for Cost Containment, 1997
20. Appelbaum PS. Clinical practice. Assessment of patients competence to consent to treatment. N Engl J Med 2007; 357: 1834-40
21. Italian Medicines Agency (AIFA) Research & Development Working Group. Feasibility and challenges of independent research on drugs: the Italian medicines agency (AIFA) experience. Eur J Clin Invest 2010; 40: 69-86
22. Friedman A, Robbins E, Wendler D. Which benefits of research participation count as direct? Bioethics 2012 Feb; 26 (2): 60-7
23. Wall A. Including persons with Alzheimer disease in research on comorbid conditions. IRB 2009; 31 (1): 1-6
24. Kim SYH, Karlawish JHT, Caine ED. Current state of research on decision-making competence of cognitively impaired elderly persons. Am J Ger Psychiatry 2002; 10: 151-65
25. Dunn LB, Nowrangi MA, Palmer BW, et al. Assessing decisional capacity for clinical research or treatment: a review of instruments. Am J Psychiatry. 2006; 163: 1323-34
26. Sullivan K. Neuropsychological assessment of mental capacity. Neuropsychol Rev 2004; 14: 131-42
27. Stewart PM, Stears A, Tomlinson JW, et al. Regulation: the real threat to clinical research. BMJ 2008; 337: a1732. doi: 10.1136/bmj.a1732
28. McMahon AD, Conway DI, Macdonald TM, et al. The unintended consequences of clinical trials regulations. PLoS Med 2009; 3: e1000131
29. Traversa G, Sagliocca L, Liberati A, et al. The need to promote independent research on drugs [letter]. Ann Oncol 2010; 21: 2295
30. Saks ER, Dunn LB, Wimer J, et al. Proxy consent to research: the legal landscape. Yale J Health Policy Law Ethics 2008; 8: 37-92
31. Schneider LS, Tariot PN, Lyketsos CG, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001; 9: 346-60
32. Kim SY, Appelbaum PS, Jeste DV, et al. Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations. Am J Psychiatry 2004; 161: 797-806
33. National Bioethics Advisory Commission. Research involving persons with mental disorders that may affect decision-making capacity. Vol. 1. Report and recommendations of the National Bioethics Advisory Commission. Rockville (MD): US Government Printing Office, 1998
34. Stocking CB, Hougham GW, Baron AR, et al. Are the rules for research with subjects with dementia changing? Views from the field. Neurology 2003; 61: 1649-51
35. Landhuis E. AD research participation: informed consent complicates trials, part 2. Subject protection versus research progress: debate continues. Alzheimer Research Forum [online]. Available from URL: http://www.alzforum. org/new/detailprint.asp?id=1868 [Accessed 2012 Apr]
36. European Parliament and the Council of the European Union. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products of human use. Official Journal of the European Communities 2001 May 1; L121: 34-44
37. Dementia in Europe Yearbook 2009. Luxembourg: Alzheimer Europe, 2009
38. Warner J, Nomani E. Giving consent in dementia research. Lancet 2008; 372: 183-5
39. Draper B, Peisah C, Snowdon J, et al. Early dementia diagnosis and the risk of suicide and euthanasia. Alzheimers Dement 2010; 6: 75-82
40. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8 (2): 151-7
41. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 2010; 87: 351-5